Ovarian cancer: predictors of early-stage diagnosis

Morris, Cyllene R.; Sands, Mollie T.; Smith, Lloyd H.

doi:10.1007/s10552-010-9547-0

Cited by 44 publications

(30 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies in the USA found no associations between measures such as area-based median length of education, household income, composite socioeconomic measures or marital status with stage of ovarian cancer [29,30]. Having no health insurance or being underinsured [30,31] and older age were, however, related to advanced stage [29,30]. Also a tendency was found that advanced stage was more frequent among women from deprived than affluent areas in Scotland [32], but this was not found in East of England [33].…”

Section: Cancer Stagementioning

confidence: 93%

“…As ovarian cancer often presents with non-specific symptoms [34], there might be little potential for socioeconomic factors to have an influence on health care seeking. Also, early and advanced ovarian cancers may be of different molecular origins, one progressing from benign lesions to malignity and the other starting as high-grade tumours [30,35]; and the capacity to recognize high-grade types at an early stage is presumably low.…”

Section: Cancer Stagementioning

confidence: 99%

See 1 more Smart Citation

Do stage of disease, comorbidity or access to treatment explain socioeconomic differences in survival after ovarian cancer? – A cohort study among Danish women diagnosed 2005–2010

Ibfelt

Dalton

Høgdall

et al. 2015

Cancer Epidemiology

View full text Add to dashboard Cite

Section: Cancer Stagementioning

confidence: 93%

Section: Cancer Stagementioning

confidence: 99%

Do stage of disease, comorbidity or access to treatment explain socioeconomic differences in survival after ovarian cancer? – A cohort study among Danish women diagnosed 2005–2010

Ibfelt

Dalton

Høgdall

et al. 2015

Cancer Epidemiology

View full text Add to dashboard Cite

“…While 97% of gynecologic oncologists perform all of the surgical procedures necessary to adequately stage women with ovarian cancer, this procedure is only accomplished by 52% of general obstetrician gynecologists and 35% of general surgeons [29]. In a study of factors associated with the diagnosis of early stage ovarian cancer Black women were less likely to be diagnosed with early ovarian cancer than White women (overall response (OR) = 0.78, 95% confidence interval (CI), 0.55-0.92) [25]. Ethnic and racial minorities and poor women are less likely to receive surgical treatment or care by a high-volume surgeon specializing in gynecologic oncology [16,23,26,30].…”

Section: Ovarian Cancermentioning

confidence: 99%

Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology

Collins

Holcomb

Chapman‐Davis

et al. 2014

Gynecologic Oncology

196

155

View full text Add to dashboard Cite

Objectives To review the extent of health disparities in gynecologic cancer care and outcomes and to propose recommendations to help counteract the disparities. Methods We searched the electronic databases PubMed and the Cochrane Library. We included studies demonstrating quantifiable differences by race and ethnicity in the incidence, treatment, and survival of gynecologic cancers in the United States (US). Most studies relied on retrospective data. We focused on differences between Black and White women, because of the limited number of studies on non-Black women. Results White women have a higher incidence of ovarian cancer compared to Black women. However, the all-cause ovarian cancer mortality in Black women is 1.3 times higher than that of White women. Endometrial and cervical cancer mortality in Black women is twice that of White women. The etiology of these disparities is multifaceted. However, much of the evidence suggests that equal care leads to equal outcomes for Black women diagnosed with gynecologic cancers. Underlying molecular factors may play an additional role in aggressive tumor biology and endometrial cancer disparities. Conclusion Gynecologic cancer disparities exist between Black and White women. The literature is limited by the lack of large prospective trials and adequate numbers of non-Black racial and ethnic groups. We conclude with recommendations for continued research and a multifaceted approach to eliminate gynecologic cancer disparities.

show abstract

“…The five main immunohistological subtypes (by order of incidence: high-grade serous, endometrioid, clear cell, low-grade serous, and mucinous) differ vastly in terms of their stage of presentation [18], chemosensitivity [19], overall survival, and driver genetic mutations [20]. Within high-grade serous ovarian cancer, numerous studies have demonstrated heterogeneity at the level of gene sequence, gene expression, copy number, or methylation [21–27].…”

Section: Prediction Of Responsementioning

confidence: 99%

Prediction of anti-angiogenesis escape

Mitamura

Gourley

Sood

2016

Gynecologic Oncology

View full text Add to dashboard Cite

Many clinical trials have demonstrated the benefit of anti-angiogenesis therapy in the treatment of gynecologic cancer. However, these benefits have often been in terms of progression-free rather than overall survival and in some cases, the magnitude of benefit demonstrated in the pivotal phase 3 trials has been disappointing when compared with the percentage of patients who responded in earlier phase 2 trials. Two potential explanations for this are the current inability to stratify patients according to chance of benefit and the development of resistance mechanisms within the tumor. In this article, we review the prediction of response and the proposed resistance and escape mechanisms involved in anti-angiogenesis therapy, including the up-regulation of alternative proangiogenic pathways, vascular co-option, and resistance to hypoxia. These insights may offer a personalized strategy for anti-angiogenesis therapy and help us to consider the best selection of other therapies that should be combined with anti-angiogenesis therapy to improve the outcome of patients with gynecologic cancer.

show abstract

Ovarian cancer: predictors of early-stage diagnosis

Abstract: These findings suggest that, in addition to tumor biology, disparities in access to care may have a significant effect on the timely diagnosis of epithelial ovarian cancer.

Cited by 44 publications

References 37 publications

Do stage of disease, comorbidity or access to treatment explain socioeconomic differences in survival after ovarian cancer? – A cohort study among Danish women diagnosed 2005–2010

Do stage of disease, comorbidity or access to treatment explain socioeconomic differences in survival after ovarian cancer? – A cohort study among Danish women diagnosed 2005–2010

Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology

Prediction of anti-angiogenesis escape

Contact Info

Product

Resources

About